Diagnostic tools for early detection of cardiac dysfunction in childhood cancer survivors: Methodological aspects of the Dutch late effects after childhood cancer (LATER) cardiology study - 18/12/19
, Helena J.H. van der Pal, MD, PhD b, Wouter E.M. Kok, MD, PhD a, Annelies M.C. Mavinkurve-Groothuis, MD, PhD b, Livia Kapusta, MD, PhD d, e, Yigal M. Pinto, MD, PhD a, Angela H.E.M. Maas, MD, PhD f, Louise Bellersen, MD, PhD f, Arco J. Teske, MD, PhD b, g, Cécile M. Ronckers, PhD b, c, Marloes Louwerens, MD, PhD h, Elvira C. van Dalen, MD, PhD b, Eline van Dulmen-den Broeder, MD, PhD i, Lilian Batenburg, MD, PhD b, p, Margriet van der Heiden-van der Loo, PhD k, Marry M. van den Heuvel-Eibrink, MD, PhD b, Flora E. van Leeuwen, PhD l, Andrica C.H. de Vries, MD, PhD m, Gert Weijers, PhD n, Chris L. de Korte, PhD n, Jacqueline J. Loonen, MD, PhD o, Sebastian J.C.M.M. Neggers, MD, PhD j, A.B. Birgitta Versluys, MD, PhD b, Wim J.E. Tissing, MD, PhD p, Leontien C.M. Kremer, MD, PhD b, con behalf of the LATER Study Group
Abstract |
Background |
Cancer therapy-related cardiac dysfunction and heart failure are major problems in long-term childhood cancer survivors (CCS). We hypothesize that assessment of more sensitive echo- and electrocardiographic measurements, and/or biomarkers will allow for improved recognition of patients with cardiac dysfunction before heart failure develops, and may also identify patients at lower risk for heart failure.
Objective |
To describe the methodology of the Dutch LATER cardiology study (LATER CARD).
Methods |
The LATER CARD study is a cross-sectional study in long-term CCS treated with (potentially) cardiotoxic cancer therapies and sibling controls. We will evaluate 1) the prevalence and associated (treatment related) risk factors of subclinical cardiac dysfunction in CCS compared to sibling controls and 2) the diagnostic value of echocardiography including myocardial strain and diastolic function parameters, blood biomarkers for cardiomyocyte apoptosis, oxidative stress, cardiac remodeling and inflammation and ECG or combinations of them in the surveillance for cancer therapy-related cardiac dysfunction. From 2017 to 2020 we expect to include 1900 CCS and 500 siblings.
Conclusions |
The LATER CARD study will provide knowledge on different surveillance modalities for detection of cardiac dysfunction in long-term CCS at risk for heart failure. The results of the study will enable us to improve long-term follow-up surveillance guidelines for CCS at risk for heart failure.
Le texte complet de cet article est disponible en PDF.Plan
| Netherlands Trial Registry (NTR) number 7481. |
|||||||
| Funding: Dutch Heart Foundation Grant [CVON2015–21]. Kika/ODAS Grant 171 ‘DCOG LATER program’. |
|||||||
The LATER Study Group also includes the following collaborative authors:
|
Vol 219
P. 89-98 - janvier 2020 Retour au numéro
Article précédent
- Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States
- Christopher P. Cannon, James A. de Lemos, Robert S. Rosenson, Christie M. Ballantyne, Yuyin Liu, Daniel Yazdi, Mary Elliott-Davey, Katherine E. Mues, Deepak L. Bhatt, Mikhail N. Kosiborod, GOULD Investigators
- “Endothelial Dysfunction in esuscitated ardiac rrest (ENDO-RCA): Safety and efficacy of low-dose Iloprost, a prostacyclin analogue, in addition to standard therapy, as compared to standard therapy alone, in post-cardiac-arrest-syndrome patients.”
- Anna S.P. Meyer, Per I. Johansson, Jesper Kjaergaard, Martin Frydland, Martin A.S. Meyer, Hanne Hee Henriksen, Jakob H. Thomsen, Sebastian C. Wiberg, Christian Hassager, Sisse R. Ostrowski
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?